About Nuclera Nucleics
Nuclera Nucleics is a company based in Cambridge (United Kingdom) founded in 2013 by Michael Chen and Gordon McInroy. Nuclera Nucleics has raised $176.2 million across 14 funding rounds from investors including E Ink, M&G and G. K. Goh Holdings. The company has 134 employees as of December 31, 2023. Nuclera Nucleics has completed 1 acquisition, including E Ink. Nuclera Nucleics offers products and services including eProtein Discovery System, Instrument, Cartridge, Reagents, and Software. Nuclera Nucleics operates in a competitive market with competitors including Encodia, Tierra Biosciences, Amide Technologies, mk2 Biotechnologies and Kesmalea, among others.
- Headquarter Cambridge, United Kingdom
- Employees 134 as on 31 Dec, 2023
- Founders Michael Chen, Gordon McInroy
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nuclera Ltd
- Date of Incorporation 27 Aug, 2013
- Jurisdiction CAMBRIDGE, UNITED KINGDOM
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nuclera Nucleics
Nuclera Nucleics offers a comprehensive portfolio of products and services, including eProtein Discovery System, Instrument, Cartridge, Reagents, and Software.
End-to-end system for rapid protein synthesis and screening in drug discovery
Device for cell-free protein expression and purification
Component for protein synthesis workflows
Materials for protein expression and optimization
Interface for managing protein prototyping processes
People of Nuclera Nucleics
Unlock access to complete
Unlock access to complete
Funding Insights of Nuclera Nucleics
Nuclera Nucleics has successfully raised a total of $176.2M across 14 strategic funding rounds. The most recent funding activity was a Series C round of $12 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nuclera Nucleics
Nuclera Nucleics has secured backing from 17 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include E Ink, M&G and G. K. Goh Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Patient Square Capital is focused on health care investments.
|
Locked | Locked | Locked | |
|
Venture capital co-investments are made in UK later-stage businesses.
|
Locked | Locked | Locked | |
|
Venture capital investments are made in life sciences and deep tech.
|
Locked | Locked | Locked |
Investor details for Nuclera Nucleics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nuclera Nucleics
Nuclera Nucleics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include E Ink.
Investment portfolio details for Nuclera Nucleics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Electronic paper displays for eBooks and devices are manufactured.
|
Locked | Locked | 1997 | Locked |
Complete acquisition details for Nuclera Nucleics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Nuclera Nucleics
Detailed financials for Nuclera Nucleics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nuclera Nucleics Comparisons
Peer comparison for Nuclera Nucleics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nuclera Nucleics
Nuclera Nucleics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Encodia, Tierra Biosciences, Amide Technologies, mk2 Biotechnologies and Kesmalea, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Technology platforms for integrative proteomic analysis are developed.
|
|
| Locked | Locked | Locked |
AI-based tools for protein development and custom synthesis are offered.
|
|
| Locked | Locked | Locked |
Automated peptide synthesis platform is developed with precision reagents.
|
|
| Locked | Locked | Locked |
Peptides and proteins are developed for life science applications.
|
|
| Locked | Locked | Locked |
Protein homeostasis modulators are developed for therapeutic applications.
|
Detailed competitors of Nuclera Nucleics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nuclera Nucleics
Complete news archive for Nuclera Nucleics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nuclera Nucleics
Nuclera Nucleics was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Nuclera Nucleics is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Michael Chen is the current CEO of Nuclera Nucleics. They have also founded this company.
Nuclera Nucleics is a funded company, having raised a total of $176.2M across 14 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Nuclera Nucleics is 134.
Founded in 2013 in Cambridge, United Kingdom, the company operates in the biotechnology sector. A desktop bioprinter known as eProtein is developed by combining eProtein synthesis with eDrop digital microfluidics technology. High-value proteins are produced through this system, enabling on-demand gene and protein synthesis. Operations focus on advancing accessible tools for biological research and applications.
Nuclera Nucleics's top competitors include Encodia, Tierra Biosciences and Amide Technologies.
Nuclera Nucleics offers eProtein Discovery System, Instrument, Cartridge, Reagents, and Software.
Nuclera Nucleics has made 1 acquisition, including E Ink.
Nuclera Nucleics has 17 investors. Key investors include E Ink, M&G, G. K. Goh Holdings, Elevage Medical Technologies, and Patient Square Capital.
The valuation of Nuclera Nucleics is $161.23M as of Dec 2021.